TIPS for Prevention of Recurrent Bleeding in Patients with Cirrhosis: Meta-analysis of Randomized Clinical Trials1
Angelo Luca, MD,
Gennaro D'Amico, MD,
Roberto La Galla, MD,
Massimo Midiri, MD,
Alberto Morabito, MS and
Luigi Pagliaro, MD
1 From the Departments of Radiology (A.L., R.L.G., M.M.) and Internal Medicine (G.D.) and the Institute of Internal Medicine and Pneumology (A.L., L.P.), University of Palermo, Ospedale V Cervello, Via Trabucco 180, 90146 Palermo, Italy, and the Institute of Medical Statistics and Biometry, University of Milan, Italy (A.M.). Received May 1, 1998; revision requested July 6; revision received August 26; accepted January 25, 1999. Address reprint requests to A.L.
View larger version (20K):
[in a new window]
|
Figure 1. Point estimates (•) and 95% CIs (horizontal bars) of the risk difference between TIPS creation and conventional treatment show that TIPS creation significantly reduces the risk of recurrent bleeding. Risk differences represented to the left of the 0-difference line (the equivalence line) denote an advantage for TIPS creation; those to the right denote an advantage for conventional therapy (CT). CI bars that do not cross the 0-difference line denote a statistically significant advantage. "Overall" denotes the pooled risk difference. Trials reported in full articles are listed before those reported in abstracts, and all are listed in ascending order of year of publication. Each trial is identified by the name of the first author. z = z value, 2P = two-sided P value, #Pts = number of patients included in each trial.
|
|
View larger version (19K):
[in a new window]
|
Figure 2. Point estimates (•) and 95% CIs (horizontal bars) of the risk difference between TIPS creation and conventional treatment show that TIPS creation significantly increases the risk of portosystemic encephalopathy. Risk differences represented to the left of the 0-difference line (the equivalence line) denote an advantage for TIPS creation; those to the right denote an advantage for conventional therapy (CT). CI bars that do not cross the 0-difference line denote a statistically significant advantage. "Overall" denotes the pooled risk difference. Trials reported in full articles are listed before those reported in abstracts, and all are listed in ascending order of year of publication. Each trial is identified by the name of the first author. z = z value, 2P = two-sided P value, #Pts = number of patients included in each trial.
|
|
View larger version (20K):
[in a new window]
|
Figure 3. Point estimates (•) and 95% CIs (horizontal bars) of the risk difference between TIPS creation and conventional treatment show that TIPS creation does not affect the risk of death due to all causes. Risk differences represented to the left of the 0-difference line (the equivalence line) denote an advantage for TIPS creation; those to the right denote an advantage for conventional therapy (CT). CI bars that do not cross the 0-difference line denote a statistically significant advantage. "Overall" denotes the pooled risk difference. Trials reported in full articles are listed before those reported in abstracts, and all are listed in ascending order of year of publication. Each trial is identified by the name of the first author. z = z value, 2P = two-sided P value, #Pts = number of patients included in each trial.
|
|
View larger version (17K):
[in a new window]
|
Figure 4. Point estimates (•) and 95% CIs (horizontal bars) of the risk difference between TIPS creation and conventional treatment show that TIPS creation does not significantly reduce the risk of death due to recurrent bleeding. Risk differences represented to the left of the 0-difference line (the equivalence line) denote an advantage for TIPS creation; those to the right denote an advantage for conventional therapy (CT). CI bars that do not cross the 0-difference line denote a statistically significant advantage. "Overall" denotes the pooled risk difference. Trials reported in full articles are listed before those reported in abstracts, and all are listed in ascending order of year of publication. Each trial is identified by the name of the first author. z = z value, 2P = two-sided P value, #Pts = number of patients included in each trial.
|
|
Copyright © 1999 by the Radiological Society of North America.
